[Federal Register Volume 66, Number 249 (Friday, December 28, 2001)]
[Notices]
[Page 67268]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 01-31879]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration


Cardiovascular and Renal Drugs Advisory Committee; Notice of 
Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

    This notice announces a forthcoming meeting of a public advisory 
committee of the Food and Drug Administration (FDA). The meeting will 
be open to the public.
    Name of Committee: Cardiovascular and Renal Drugs Advisory 
Committee.
    General Function of the Committee: To provide advice and 
recommendations to the agency on FDA's regulatory issues.
    Date and Time: The meeting will be held on January 17 and 18, 2002, 
from 8:30 a.m. to 4:30 p.m.
    Location: Holiday Inn, Kennedy Ballroom, 8777 Georgia Ave., Silver 
Spring, MD.
    Contact: Jaime Henriquez, Center for Drug Evaluation and Research, 
(HFD-21), Food and Drug Administration, 5600 Fishers Lane (for express 
delivery, 5630 Fishers Lane, rm. 1093), Rockville, MD 20857, 301-827-
7001 or FDA Advisory Committee Information Line, 1-800-741-8138 (301-
443-0572 in the Washington, DC area), code 12533. Please call the 
Information Line for up-to-date information on this meeting.
    Agenda: On January 17, 2002, the committee will discuss new drug 
application (NDA) 20-757/S-021, AVAPRO (irbesartan), Sanofi-Synthelabo 
(c/o Bristol-Myers Squibb), for the treatment of hypertensive patients 
with type 2 diabetic renal disease. On January 18, 2002, the committee 
will discuss NDA 21-387, pravastatin/aspirin, Bristol-Myers Squibb, co-
package, for long-term management to reduce the risk of death, nonfatal 
myocardial infarction, myocardial revascularization procedures, and 
ischemic stroke in patients with clinically evident coronary heart 
disease.
    Procedure: Interested persons may present data, information, or 
views, orally or in writing, on issues pending before the committee. 
Written submissions may be made to the contact person by January 7, 
2002. Oral presentations from the public will be scheduled each day 
between approximately 1 p.m. and 2 p.m. Time allotted for each 
presentation may be limited. Those desiring to make formal oral 
presentations should notify the contact person before January 7, 2002, 
and submit a brief statement of the general nature of the evidence or 
arguments they wish to present, the names and addresses of proposed 
participants, and an indication of the approximate time requested to 
make their presentation.
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).

    Dated: December 14, 2001.
Linda A. Suydam,
Senior Associate Commissioner.
[FR Doc. 01-31879 Filed 12-27-01; 8:45 am]
BILLING CODE 4160-01-S